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Idiopathic pulmonary Fibrosis (IPF) is a chronic lung disease with median survival about 2-3.5 
years (1). Lung transplant is the most effective therapy although pirfenidone (2) and nintetanib 
(3) delay mortality or disease progression. Biomarkers are used for diagnosis and management of 
diseases (4) but for IPF, a reliable biomarker is not established (5, 6).  In this project, we 
proposed to investigate lung transcript expressions and plasma proteins as diagnostic or 
prognostic biomarkers and their implication in Pathogenesis of IPF.  
First, we found 44 transcripts qualified after t-test, Benjamini and Hochberg multiple 
correction, and 1.5-fold change cutoff.  We observed 33 transcripts that commonly distinguished 
IPF from control or COPD.  The scoring coefficients of the principal components (COMP) 
distinguished IPF from control or COPD by using Classification Tree model.  The receiver 
operating characteristic (ROC) curves for scoring coefficients of COMP of IPF vs control was 
with Area Under Curve (AUC) = 0.90 (95% CI), sensitivity 85% and specificity 91%  and  IPF 
or COPD was AUC= 0.88 (95% CI), sensitivity 86 % and specificity 90%. 
Second, we measured 24 biomarkers in IPF plasma using Searchlight Protein Array. In 
cross-sectional study, intercellular adhesion molecule 1 (ICAM), vascular cell adhesion molecule 
1 (VCAM1), and S100 calcium binding protein A12 (S100A12), and surfactant protein D 
(SFTPD) were predictors of IPF mortality (P < 0.05).  In serial studies, previously identified 
proteins ICAM1, VCAM1, S100A12, interleukin 8 (IL8) and novel proteins matrix 
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metallopeptidase 10 (MMP10) and tissue inhibitor of metalloproteinase 1 (TIMP1) were 
predictors of IPF mortality.  
Third, we discovered in lung fibroblasts from IPF a deficiency of E2F transcription factor 
8 (E2F8), which is eliminated by an F-box protein 16 (FBXO16).  Biologically, E2F8 reduces 
fibroblast proliferation, and E2F8 also decreases collagen 1A1 mRNA synthesis.  Hence, we 
found a model of lung fibrosis focusing on two novel molecular inputs (E2F8 and FBXO16) 
linked to fibroblast behavior in subjects with IPF.   
In summary, our transcriptomic and plasma proteins analyses revealed the utility of 
biomarker discovery in advancing precision medicine in IPF.  Together these finding provide 
novel insights that may improve IPF diagnosis, prognostic and potential drug discovery.   
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 INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a devastating and incurable disease with a ~3 year median 
survival time (1). IPF affects 185,000 subjects in the United States (7) and pathogenesis of IPF is 
not well understood. Previously, it was suggested that pulmonary inflammation initiates the 
process of fibrosis. To date, the paradigm has  moved  to alveolar epithelial cells malfunction and 
muddled fibroproliferstion (8). The clinical characteristics of IPF diseases  is heterogeneous; 
stable IPF with slow decline, rapid deterioration, and time of stability intermingled with periods 
of decline (8). Lung transplantation remains to be the most beneficial therapy(9) although Ofev 
(nintedanib) and Esbriet (Pirfeniodone) were reported to reduce disease progression among some 
IPF individuals. No single biomarker is used in clinical setting for diagnosis, disease 
susceptibility, disease prognosis, disease activity, drug efficacy, and stratification of patients for 
lung transplant (5, 6, 10). Therefore, novel approaches investigating IPF Biomarkers may deliver 
potential mechanism of IPF, discovery of novel drugs and will have public health impacts. 
The diagnosis of IPF is based on the recommendations of ATS and ERS guidelines for 
diagnosis (11). IPF has been recognized as a chronic, progressive interstitial lung disease.  The 
Histologic and high resolution computer tomographic scan findings are typically usual interstitial 
pneumonia (UIP) pattern, comprising of reticular irregularities in subpleural distribution with 
honeycombing (subpleural cysts). The UIP histology is also described as temporally 
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heterogeneous area of fibrosis and subepithelial fibroblastic foci.  The descripted fibroblastic foci 
is mainly collection of active proliferative myofibroblasts and fibroblasts(12). IPF is an exclusion 
diagnosis of other interstitial lung diseases and bronchoscopy procedures are sometimes 
preformed to collect bronchoalvealar fluid [BALF] in order to determine the etiologies of the 
diseases although it is not necessary required for diagnosis of IPF.  It remains difficult and 
expensive to make diagnosis of IPF because excluding all other types of interstitial lung diseases 
is critically important. Moreover, sometimes physicians recommend lung biopsy, which is 
invasive and very expensive procedure. 
In general, biomarkers function either as surrogates for clinical meaningful outcomes that 
may or may not reveal the mechanism of the disease. For IPF, clinical relevant biomarkers could 
be for diagnosis, prognostication of mortality, and stratification of patients for surgical 
procedures.  Easily obtainable, measurable, reproducible and reliable biomarkers would serve as 
perfect markers for serial clinical observation. This is ideal for IPF since the diagnosis is made 
by using information from radiological imaging and biopsy plus clinical history. The diagnosis 
of IPF is mainly made by expert physicians in the field of interstitial lung diseases who work in 
tertiary hospitals and they are not available to many patients due to the geographical location. 
Therefore peripheral blood biomarkers that can serve as diagnostic tools for IPF would help 
patients and primary physicians to discover illness earlier.  Furthermore, predictive biomarkers 
could identify the effectiveness of current available drugs and drug in clinical trials to monitor 
disease activity in a longitudinally study. We focused here on diagnostic and prognostic 
biomarkers because they are relevant and achievable goals in multicenter research to validate and 
apply to clinical settings. 
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Peripheral blood proteins have been studied in the last decades in an attempt to distinguish 
IPF from control and other diseases.  This include matrix metalloptroteinase 7 (MMP7), MMP1 
(13), mucin 1, cell surface associated (aka Krebs von den lungen 6) (14) surfactant protein A1 
(SFTPA1) (15), alpha defensins (16), and secreted phosphoprotein 1 (SPP1 aka osteopontin) 
(17).  Unfortunately, many of these markers are also increased in the blood of patients with other 
types of interstitial diseases(18).  A single diagnostic biomarker may not be accurate due to 
several confounding factors like smoking; instead we suggest a panel of biomarkers may perform 
better in IPF diagnosis in the clinical settings. 
Prognostic biomarkers are either genes or proteins that predict outcomes and have had 
extensive study in IPF.  The blood proteins suggested as prognostic biomarkers include: fibulin 1 
(19),  MUC1 (20), C-X-C motif chemokine ligand 13 (CXCL13) (21), MUC5B (22), lysyl 
oxidase like 2 (LOXL2) (23) periostin (POSTN) (24), chitinase 3 like 1 (CHI3L1 aka YKL40) 
(25), MMP1, C-C motif chemokine ligand 18 (CCL18), SFTPA1,  and SFTPD (15).  Blood cells 
that have been identified as predictors of mortality in IPF subjects include: CD4(+)CD28(null) T 
cells (26), CD4(+)CD25(+)FOXP3(+) regulatory T cells (27), semaphorin a+ regulatory T cells 
(28) and fibrocytes (29).  In this current study, we replicated published prognostic biomarkers in 
peripheral blood such ICAM1, S100A12, SFTPD, and VCAM1 in cross-section studies (30).  A 
novel finding of this project is the discovery of 5 longitudinal biomarkers for IPF by using 250 
blood plasma samples in serial collection.  Time-dependent Cox proportional hazards model was 
applied to predict the mortality of IPF subjects. This study revealed reliable and reproducible 
peripheral blood biomarkers that could be used as prognostic biomarkers for IPF subjects and 
provided new insights into our understanding of IPF pathogenesis 
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Collagen 1A1 (COL1A1) and elastin (ELN) are excessively deposited in the IPF lungs 
compared to healthy subjects (31) (32) and can be regulated by transforming growth factor β1 
(TGFB1).  E2 transcriptional factor 8 (E2F8) is a member of E2F transcription factors.  The E2F 
protein family is divided into two groups, transcriptional activators (E2F1-3) and transcriptional 
repressors (E2F4-8).  E2Fs engage other factors such as retinoblastoma protein (Rb) or 
dimerization partner (DP) proteins to control gene transcription (33).  E2F1 deficient mice have 
more biliary fibrosis through early growth response 1 (EGR-1) (a zinc finger protein) (34), but 
overexpression of E2F1 inhibits COL2A1 formation in cartilage (35).  None of the E2 family 
members have been studied on pulmonary fibrosis.  In this study, we examined the level of E2F8 
mRNA and   Verified E2F8 protein level in IPF lungs, fibroblasts and bleomycin induced mice 
lung fibrosis were conducted. We hypothesized that E2F8 is targeted for ubiquitination and 
proteasomal degradation in human lung fibroblasts (hLF), which is mediated by F-box protein 16 
(FBXO16). The loss of E2F8, in turn, leads to increased COL1A1 synthesis in IPF lung.  Human 
lung fibroblasts (hLF) transfected with Myc-tagged E2F8 plasmids encoding E2F8 suppressed 
fibroblasts proliferation or COL1A1 synthesis.  Transfection with a short hairpin RNA (shRNA) 
constructs directed at E2F8 induced fibroblasts proliferation or COL1A1 synthesis.  To examine 
the promoter activities of COL1A1, hLF were transfected with a plasmid containing a COL1A1 
promoter, luciferases reporter construct (GLucCOL1A1), with a E2F8 plasmid, or with E2F8 
shRNA. In this project we investigated extra cellular matrix accumulation of collagen 1A1 in the 
IPF lung and the involvement of transcription factor E2F8 plus FBX016 in the IPF disease. 
Taken together, this project suggests a basis for future research on diagnostic or 
prognostic biomarkers of IPF and implication of E2F8 and FBX016 in IPF pathogenesis.
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 PAPER 1: POTENTIAL DIAGNOSTIC BIOMARKERS OF IDIOPATHIC 
PULMONARY FIBROSIS (IPF) 
2.1 INTRODUCTION 
IPF is an utmost lethal and refractory type of Usual Interstitial Pneumonias (UIP). IPF is an 
incurable disease with a survival typically less than 4 years (8).  The diagnosis of IPF is made by 
excluding other interstitial lung diseases (ILDs).  Histological findings of IPF are characterized 
by patchy foci of fibroblast proliferation activities, inflammatory activities, areas of intensive 
fibrosis (honeycombing), intersperse with areas of healthy lung (36).  High Resolution Computer 
Tomography (HRCT) is useful in diagnosing IPF (9) and predicting mortality (37).  Several 
environmental and genetic factors have been suggested to contribute to IPF risk including 
cigarette smoking (38), drug exposure, and viral infection (39, 40).  In United States about 24 
million adults have abnormal lung function (41, 42) and majority of the deaths can be ascribed to 
chronic obstructive pulmonary disease (COPD) with at least 15,000 deaths can be ascribed to 
IPF (43, 44).   
Transcriptomic methods have been extensively used in cancer investigations to classify 
known or novel disease phenotypes. Scientists documented types of diffuse large B cell 
lymphoma and other hematological malignancies (45), foretelling the prognosis of solid tumors, 
metastases and forecasting efficacy of therapies in malignancies (46-48). These methodologies 
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have yet to be fully used in the field of pulmonary medicine to study IPF, COPD or other 
pulmonary diseases. Nevertheless, the latest studies investigating pulmonary diseases with 
similar techniques using large cohorts have contributed to significant understandings of 
methodology and outcomes of IPF (49-51). 
 Therefore, we undertook this study using transcriptomics and bioinformatics modeling to 
distinguish IPF from control or COPD subjects and to examine the functions of transcriptomic 
signatures that distinguish IPF from control subjects.  
2.2 METHODS 
 Samples collection for Microarrays 
Lung Genomics Research Consortium (LGRC) was formed in 2009 by principal investigators 
from Boston University, University of Colorado, Dana-Faber Cancer Institute, University of 
Michigan, Mayo Clinic, National Jewish Health, and University of Pittsburgh. It was funded by 
National Heart, Lung, and Blood Institute (NHLBI) on behalf of National Institute of Health 
(NIH) through the recovery and Reinvestment Act (ARRA) of 2009.  The samples for this study 
were obtained from Lung Tissues Research Consortium (LTRC), a project funded by NIH.  The 
clinical and genomic data of LTRC and LGRC is available for scientists to understand the 
genomics basis of chronic obstructive pulmonary disease (COPD), Idiopathic Pulmonary 
Fibrosis (IPF) and other interstitial lung diseases (ILD).  
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 Microarray Data 
We analyzed RNA snap frozen tissues and de-identified demographics, pulmonary function 
testing, HRCT, pathological diagnosis and clinical information.  Samples were placed in ice cold 
Trizol, total RNA was extracted and used as a template for double stranded cDNA synthesis.  
RNA quantity was determined by spectrometry (260nm) and its integrity by Agilent Bioanalyzer 
and the calculated RNA integrity number (RIN>8).  
 Planning and design of microarray experiments – A limitation in design and planning of 
large scale microarray experiments is the potential for batch effects.  To address this concern, we 
applied block designs to ensure that control RNA (normal lung) was used in every batch. The 
unique design of the Agilent arrays (4 samples per slide) and the high throughput of the array 
scanner (48 slides) reduced samples variability.   
Array analysis: After quality control and LOESS normalization, differentially expressed genes 
was identified by using the extensive tools in the ScoreGenes package (52) as well as Significant 
Analysis of Microarrays (SAM) (53) applying Bioconductor (54, 55).  Sam is a statistical 
technique used for identifying significant transcripts in a set of microarrays experiments (53). 
Transcripts data set generated from microarray experiments are input variables as well as 
response variable (control or disease) or multiclass grouping experiments (e.g. lung cancer, 
kidney cancer or liver cancer). For example, SAM analyzes a statistic di for every transcript i, 
considering the power of the association between the transcripts and response variables. It is 
critical to understand that SAM uses repeated permutations of transcripts data set to distinguish a 
transcript as significant related to response variable. The investigator will set up a cutoff to 
determine for significance by changing the delta parameter based to the false positive rate / false 
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negative rate or 1.5 -2 fold change parameter. To correct for multiple testing, we used the 
calculated q-value method as an extension of the false discovery rate (FDR) that is the proportion 
of transcripts likely to have been falsely classified by chance as being significant (56). Q-values 
was computed using the R package for Q calculation(52).  Initial studies focused on differences 
between IPF and control followed by IPF vs COPD transcripts analysis.  The microarray data set 
used for this research is publicly available in the NCBI/GEO repository, accession number 
GSE47460 and GSE72967, http://www.ncbi.nlm.nih.gov/geo/. The demographic and 
characteristics were obtained from the Lung Genomics Research Consortium (LGRC, 
http://www.ltrcpublic.com/ . 
 
 Statistical Analysis 
 We note that even if as few as 100 genes among the 29,232 probes with Entrez Gene IDs in the 
January 2007 annotations of the Agilent 4x44K microarray platform are differentially expressed 
with fold change of at least 1.5, the proposed study with 100 COPD patients and 60 IPF patients, 
is powered at 95%, with local FDR 0.00008. Additionally, we performed the following analysis: 
(1) The gene expressions data were log transformed, (2) two samples t-test was conducted, (3) 
p<0.05 were corrected using Benjamini and Hochberg technique (57). (4) Transcripts were 
selected based on fulfilling the critical p < 0.05 and 1.5-fold change, (5) Principal component 
analysis was performed to achieve reduction of dimensionality. Principal components analysis 
(PCA) is commonly used mathematical algorithm that aims to reduce the big data dimensionality 
while maintaining the most variations in the dataset(58). PCA utilizes identification of directions 
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that are described as principal components with maximal variation in the data set. By doing so 
several variables can be represented by few principal components. Based on the cutoff of 
cumulative proportions setup, the samples can be visualized and the similarities as well as 
differences between samples groups can be estimated. In this study 44 principle components 
where generated, however 8 principle of components were enough to offer 80% accountability 
for the variability for control vs IPF.  While 15 principle components out of 69 principle 
components offered 80% accountability for the variability for COPD vs IPF. 
 (6) The prediction coefficient of IPF vs Control, and IPF vs COPD were conducted through 
logistic regression, (6) The classification tree model discriminates between outcomes (e.g. 
diseases vs control). The model looks for the choices of the predictive biomarkers and create the 
spilt that exploit the like-hood of the available dataset.  Again within each subsequent subset, the 
algorithm examines the level of each variables to indicate the best split (nodes). This process 
continue until all subjects are perfectly discriminated, or the sample size becomes very small to 
be divided. The classification trees model was used to identify potential combination of the 
prediction coefficient scores of the COMP that could be used to distinguish IPF from control or 
COPD. The analysis was conducted using the rpart package (https://www.r-project.org/) for 
recursive partitioning. The classification performance was assessed using the ROCR package 
(http://rocr.bioinf.mpi-sb.mpg.de/).   
Quality of a biomarker is a matter of concern in biomarkers development. It is essential that a 
biomarker can accurately distinguish between disease and control subjects. In case the 
measurement of Biomarkers is positive or negative, there will be true positive rate (TPR)/false 
positive rate (FPR).  Sensitivity and specificity are usually used for TPR as well as 1-FPR 
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We conducted the ROC analysis by extracting the pruned dataset (The classification trees model 
were pruned using 0.01).  The Y –Axis presents sensitivity and X- Axis present 1- specificity. 
The line through 450 degree is 50/50 line.  
In summary, we setup 80% variability of the transcripts to retain sufficient principal 
component number. The comparison between IPF vs control or IPF vs COPD were first obtained 
by using logistic regression model  (59) and followed by specific tests to predict probability and 
classify the diseases. These analyses were conducted using StataCorp LP, (College Station, TX) 
and R-package (https://www.r-project.org/). 
2.3 RESULTS 
 Demographic and clinical information of subjects IPF and COPD 
We extracted 78 IPF subjects, 130 control subjects, 150 COPD subjects that were recruited in 
LGRC study. The characteristics of the participants are summarized in Table 2.1  
Table 2.1: Demographic and subjects characteristic of IPF, COPD, and control. 
Definition of abbreviations: FVC = Force Vital Capacity precent predicted, FEV1 = Force 
Expiratory Volume 1 second precent predicted, and DLCO = Diffusing Capacity for Carbon 
Monoxide percent predicted. 
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Table 2-1: Demographic and subjects characterisitics of IPF, COPD and control 
Group 
FVC 
(%) 
FEV1 
(%) 
DLCO 
(%) 
Smoke home 
(%) 
Smoke work 
(%) 
Ever smoke 
(%) 
Male 
(%) Age-Mean 
N 
IPF 64.6 71.4 49.5 73.8 54.8 63.5 65.9 64.8 
 
77 
COPD 79.8 79.8 61.9 75 73.8 95 58 69.3 
 
150 
Control 94.5 94.6 82.9 62.5 45.5 44.6 50 62 
 
130 
 
 Increased transcripts in IPF compared to either control or COPD 
When IPF was compared to control samples, out of 29232 probes, 15723 transcripts were 
significantly differentially expressed at P<0.05.  After Benjamini and Hochberg multiple 
correction procedure and the assumption of 1.5 fold change cutoff, the number of candidates was 
reduced to 44 transcripts (Table 2.2).  The 5 most increased transcripts were IGFL1, ABCA12, 
LY6D, SPRR1A, and MMP13.  To understand the biological important of the transcripts, we 
performed the functional analysis with Database for Annotation, Visualization and Integrated 
Discovery (DAVID) that revealed relevant pathways as described in Table 2.3.  To investigate 
the differential expressed transcripts in IPF vs COPD, we used the same criteria for p-values and 
fold change cutoff 1.5. There were 69 transcripts that were increased in IPF and have the FC of 
1.5 compared to COPD (Table 2.4).  
Thirty three common transcripts were able to distinguish IPF from either control or 
COPD (Table 2.5). They included MMP10 that was recently identified by others and us as 
biomarkers of IPF (13, 60). 
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Table 2-2: The increased transcripts in IPF when compared to control.  
Definition of abbreviations: t-test =Two paired t-test, CTL = Control subjects, BH*0.05 = 
Benjamini and Hochberg multiple correction, FC= Fold Change.  IPF = Idiopathic pulmonary 
fibrosis 
 
Symbol Ttest_CTL_IPF Rank BH*(5%) FC Symbol 
ttest 
CTL_IPF Rank BH*(5%) FC 
IGFL2 1.3E-28 5 8.5E-06 2.2 ADAMTS18 6.5E-16 542 9.2E-05 1.6 
ABCA12 8.6E-28 11 1.8E-05 2.1 CR2 2.3E-10 2043 3.4E-04 1.5 
LY6D 5.3E-23 63 1.0E04 2.1 ADAMTS16 4.5E-16 518 8.8E-05 1.5 
SPRR1A 1.1E-27 12 2.0E-05 2.0 FLJ41200 8.6E-11 1849 3.1E-03 1.5 
MMP13 6.3E-22 90 1.0E2 1.9 DSC3 3.1E-14 835 1.4E-04 1.5 
GREM1 5.0E-24 40 6.8E-05 1.8 CLCA2 5.5E-11 1774 3.0E-03 1.5 
GPR87 8.5E-25 30 5.1E-05 1.8 VSIG1 7.8E-19 259 4.4E-04 1.5 
UGT1A8 2.2E-19 213 3.6E-04 1.8 FAM159B 9.7E-11 1873 3.2E-03 1.5 
KRT6A 2.3E-15 624 1.0E-04 1.7 FCRL5 2.7E-16 485 8.2E-04 1.5 
KRT6C 3.3E-13 1071 1.8E-04 1.7 STRA6 9.3E-21 135 2.3E-04 1.5 
UGT1A6 4.1E-18 305 5.2E-04 1.7 KRT5 2.8E-16 489 8.3E-04 1.5 
BAAT 1.0E-20 138 2.3E-04 1.7 GREM1 2.9E-22 77 1.3E-03 1.5 
TMEM229
A 2.5E-28 7 1.1E-05 1.7 FRMD5 5.4E-23 64 1.0E-04 1.5 
TMEM215 6.3E-21 127 2.1E04 1.6 CYP27C1 5.3E-17 404 6.9E-04 1.5 
TTR 5.3E-16 528 9.0E-05 1.6 PADI1 7.8E-09 2891 4.9E-03 1.5 
COL17A1 5.4E-27 15 2.5E-05 1.6 SERPINB4 9.3E-08 3659 6.2E-03 1.5 
CPNE4 1.3E-21 103 1.7E04 1.6 CXCL13 5.1E-13 1118 1.9E-03 1.5 
SERPINB5 1.3E-15 588 1.0E-03 1.6 OGDHL 1.6E-17 363 6.2E-04 1.5 
MMP10 4.3E-14 869 1.4E-03 1.6 SERPINB3 5.6E-08 3489 5.9E-03 1.5 
GLB1L3 3.9E-16 509 8.7E-04 1.6 DIO2 5.1E-19 243 4.1E-04 1.5 
MMP1 9.2E-27 17 2.9E-05 1.6 FDCSP 2.6E-11 1655 2.8E-03 1.5 
CYP24A1 3.1E-15 647 1.1E-03 1.6 GJB4 1.4E-11 1560 2.6E-03 1.5 
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Table 2-3: Functional analysis of increased transcripts in IPF compared with control.  
Two of the 9 functional annotation clusters of the transcripts that distinguished IPF from Control. 
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Table 2-4:  Increased transcripts in IPF when compared with COPD. 
The list of 69 transcripts that distinguished IPF from COPD after 1.5 FC cutoff 
Symbol Symbol Symbol Symbol 
ABCA12 KRT6A ASB5 YSK4 
IGFL2 SPOCK3 C6orf142 PMCH 
MMP13 LGSN ATP12A C3orf16 
LY6D DSG3 VTCN1 TMEM229A 
UGT1A8 CLCA2 CYP27C1 DSC3 
GPR87 VSIG1 DNAH12 ADAMTS16 
SPRR1A RIMS2 CCDC67 LRRIQ1 
UGT1A6 GLB1L3 STRA6 LEKR1 
TTR BAAT CCDC39 KLK13 
HS6ST3 GJB4 MMP10 PROM1 
CPNE4 PCSK1 UCN2 ADAMTS18 
KRT6C DIO2 FRMD5 TFAP2A 
TMEM215 GJB5 OGDHL LOC100131046 
FAM159B DACH2 NELL1 C7orf57 
CYP27C1 LOC554202 TMEM212 ANXA13 
HHLA2 C1QTNF8 DKFZp434J0226  
COL17A1 CYP24A1 ECT2L  
SERPINB5 CLDN8 KRT5  
 
 
Table 2-5: The common transcripts that distinguish IPF from either from control or COPD. 
The 33 transcripts that commonly distinguished IPF either from control or COPD subjects after 
application the reduction methods being used 
 
 
 
 
 
 
Symbol Symbol Symbol Symbol 
ABCA12 CPNE4 FRMD5 VSIG1 
IGFL2 KRT6C OGDHL GLB1L3 
MMP13 TMEM215 KRT5 BAAT 
LY6D FAM159B TMEM229A GJB4 
UGT1A8 CYP27C1 DSC3 PCSK1 
GPR87 COL17A1 ADAMTS16 DIO2 
SPRR1A SERPINB5 ADAMTS18  
UGT1A6 STRA6 KRT6A  
TTR MMP10 CLCA2  
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 The scoring coefficients of principal components distinguish IPF either from control 
or COPD subject. 
To examine whether the scoring coefficients of principal components computed from transcripts 
expression accurately classify IPF subjects from control or COPD subjects, we used recursive 
partitioning to the transcript dataset and discovered that scoring coefficients of the principal 
components distinguish IPF from COPD or control. The classification model analysis 
demonstrated that COMP1 <0.07 concentration could discriminate control from IPF with a node 
(93/14) (CONTROL/IPF) with terminal node of (91/9) while COMP1< 0.07 IPF from control 
(37/64) with terminal node (4/47) (CONTROL/IPF) (Figure 2.1A). The ROC curves for 
application of scoring coefficients of 8 principal components to categorize the samples as IPF or 
control was significant with AUC= 90% (95% CI) (Figure 2.1B), sensitivity 85% and specificity 
91% . 
Finally, after comparing IPF with control, we were curious to examine whether there 
exist difference between IPF subjects and COPD subjects in their transcript expression pattern. 
After following the same procedures above, we found that 69 transcript were increased in IPF 
compared with COPD. Furthermore, the scoring coefficients of the principal components 
differentiated COPD from IPF were 15 COMPs.  The CART analysis revealed that COMP4 
>0.02 concentration could discriminate COPD from IPF with terminal node (137/20) with 
terminal node (135/11) (COPD/IPF) while on right side of the CART, the terminal node (13/58) 
(COPD/IPF) (Figure 2.2A). The ROC curves for the scoring coefficients of 15 principal 
components to categorize the samples as IPF or COPD was significant with AUC= 88% (95% 
CI) (Figure 2.2B) sensitivity 86 % and specificity 90%. 
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          A                                                                                    B   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1: Classification tree model and ROC Curve  
A: Classification tree model generated by using scoring coefficients of 8 principal components 
for 44 IPF transcript expression and control transcript expression.  Control samples is at the left 
and IPF in the right (control/IPF) in the box. The numbers counts are control / IPF. The original 
tree has been pruned with 0.01 value of the scoring coefficients to improve the classification tree. 
The terminal nodes showed how accurate the Control or IPF were classified.  B: The ROC 
curves for application of scoring coefficients of 8 principal components to categorize the samples 
as IPF or control. On the x–axis is plotted false positive rate (1- specificity) and y–axis is 
0.90 
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sensitivity plotted. The area under curve is corresponding to the numerator of the Mann-Whitney 
U-statistic matching the scoring coefficients disseminations between IPF and control.  The red 
Line at 45 degree represents 50% classification of IPF vs control participants. 
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             A                                                                             B                                                      
 
 
 
 
 
 
 
 
 
 
Figure 2-2: Classification tree model and ROC Curve 
A: Classification tree model generated by using to scoring coefficients of 15 principal 
components for 69 IPF transcripts expression and COPD transcript expression. COPD samples is 
at the left and IPF in the right (COPD/IPF) in the box. The numbers counts are COPD / IPF. The 
original tree has been pruned with 0.01 values of the scoring coefficients to improve the 
classification tree. The terminal nodes indicate how accurate the COPD or IPF were classified. 
B: The ROC curves for application of scoring coefficients of 15 principal components to 
categorize the samples as IPF or COPD. On the x–axis is plotted false positive rate (1- 
specificity) and y–axis is sensitivity plotted. The area under curve is corresponding to the 
numerator of the Mann-Whitney U-statistic matching the scoring coefficients disseminations 
between IPF and COPD. The red Line at 45 degree represents 50% classification of IPF vs 
COPD participants. 
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2.4 DISCUSSION 
Here we have demonstrated that using advance bioinformatics modeling and computation, we 
were able to in distinguishing different types of diseases such as IPF or COPD from control. The 
differences between the two devastating diseases (IPF and COPD) could be distinguished from 
each other by using microarrays mRNA transcripts expression datasets. We were able to reduce 
29232 probes by using significant p value, Benjamini and Hochberg multiple correction and 
critical cutoff level of 1.5-fold change for IPF vs control, IPF vs COPD.  The ROC of IPF vs 
control was significant with an AUC = 0.90 (95% CI), and ROC of IPF vs COPD was significant 
with an AUC= 0.88 (95% CI). 
In this study, 44 transcripts distinguished IPF from control and are involved in several 
pathways such as cell–cell signaling, cytokine activities, response to wounding and extracellular 
matrix proteins accumulation.  These processes are consistent with activation of TGFB1 in 
pulmonary fibrosis.  TGFB1 stimulates fibroblasts to play major roles in the fibrotic foci and is a 
well-known driver of fibrotic lung remodeling.  It is possible that increased mRNA in the lung 
transcripts may serve as an indicator of active fibrotic lung remodeling.  
Transcripts expression has been previous used for cancer diagnosis and classification of 
non-Hodgkin (61).  Also the transcripts expression of prostate cancer tissues and the neighboring 
prostate cancer areas have been studied (62).  The breast cancer biomarkers (63), ovarian cancer 
biomarker (Ca -125) (64, 65) and colon cancer biomarker (CAE) have been widely studied at 
stages of the diseases and used in clinical setting (66, 67).  However, in IPF, there is no single 
clinical biomarker for diagnosis, prediction, prognostication or for predicting drug response. 
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The limitation of our study is that the IPF subjects or COPD subjects were sampled 
without categorizing them in sub-phenotypes of diseases.   Nonetheless, we used a larger dataset 
that is capable to reduce the subject to subject variations.  
Taken together, the estimate of transcripts expression can distinguish IPF from COPD or 
control.  The comparison of transcripts expression between IPF vs COPD  was possible first by 
using t-test, logistic regression model (59) and followed by specific tests to predict probability 
and classification of the diseases. Therefore, future studies to explore these methods to 
distinguish stages of disease or group of disease should be encouraged.
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 PAPER 2: CROSS-SECTIONAL AND SERIAL PERIPHERAL BLOOD 
PROTEIN PROFILES ARE PREDICTORS OF OUTCOMES IN IDIOPATHIC 
PULMONARY FIBROSIS 
3.1 INTRODUCTION 
Idiopathic pulmonary fibrosis is a chronic and lethal lung disease (11) mainly affecting the 
elderly (50 to 79 years old) and mainly males (68). To date, lung transplantation remains to be 
the most beneficial therapy for IPF.   The clinical scenarios of IPF are variable and the outcomes 
of the disease are unpredictable and there is no single reliable biomarker that has been 
established for IPF (5, 6).  Physiological and functional measurements such as six minute walk 
distance (6MWD) and pulmonary function test are not yet accepted as surrogate biomarkers for 
IPF mortality (69, 70).  However, those established measurement such as FVC, and DLCO are 
used to observe disease progression in clinical setting (71).  
In the recent years, many investigators have examined transcripts or proteins that could 
be potential biomarkers of IPF.  For example, increased MMP7 transcript and protein in serum, 
plasma and lung tissues have been noted in IPF patients and have been proposed as possible 
predictors of IPF mortality (13, 16, 30).  Similarly, circulating fibrocytes in peripheral blood, 
(29), increased Chemokine (C-C motif) ligand 18 (CCL18) (72), and mucin1, cell surface 
associated (MUC1 aka KL-6) (20) in IPF serum and C-X-C motif chemokine ligand 13 
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(CXCL13) (Chemokine Motif) in IPF plasma (21) have been advocated as predictors of 
prognosis of IPF disease. Interestingly a polymorphism of MUC5B was shown to have 
association with subgroup of IPF subject (73). Despite these persuasive studies, the need of 
reliable and reproducible peripheral blood biomarkers of IPF that support discovery of 
pathogenesis or therapeutic target of IPF remains un-met.  
In this study we replicated ICAM1, VCAM1, S100A12, IL-8 and SFTPD proteins as 
biomarkers for IPF in cross-sectional study; and MMP10, ICAM1, VCAM1, S100A12, IL8 and 
TIMP1 proteins as predictors of mortality in longitudinal study. The combined personal clinical 
and molecular mortality prediction index (PCMI) of the protein biomarkers improves the 
probability of predicting IPF mortality.  We published portions of these results as an abstract in 
American thoracic society conference book in May 2014 (74). 
3.2 METHODS 
 Searchlight Protein Array 
All patients were evaluated at the University of Pittsburgh Medical Center (UPMC) and studies 
were approved by the Institutional Review Board (IRB) at the University of Pittsburgh. The 
diagnosis of IPF was established on the basis of American Thoracic Society (ATS) and European 
Respiratory Society (ERS) criteria (11). The recruitment and data collection (75), and 61 subjects 
were recruited from ongoing study: “the Genomic and Proteomic Analysis of Disease 
Progression in Idiopathic Pulmonary Fibrosis (GAP)”. The repeated blood samples and clinical 
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assessments were collected in intervals of 3-4 months. The 24 proteins in table 1 were assessed 
in 250 samples by using Searchlight Protein Array (Aushon Biosystems, Billerica, MA). 
 
Table 3-1: Candidate proteins for outcome in Idiopathic Pulmonary Fibrosis detected in 
peripheral blood. 
 
 
 
 
 
 
 
 
 
 
 
 Microarray 
We extracted total RNA from 63 Control lungs, 154 COPD lungs, and 83 IPF lung tissues 
obtained from the Lung Tissues Research Consortium (LTRC). The experimental materials, 
Gene Symbol Proteins Ref.  in IPF 
IL1-alpha Interleukin 1, alpha  (76) 
IL2 Interleukin 2  (77) 
IL6 Interleukin 6  (78, 79) 
IL8 Interleukin 8  (80) 
IL10 Interleukin 10  (81) 
IFN -alpha Interferon, alpha  (82) 
ICAM1 Intercellular adhesion molecule 1  (30, 83) 
VCAM1 Vascular cell adhesion molecule 1  (30, 84) 
MPO Myeloperoxidase  (85) 
MIP (AQP0) Major intrinsic protein of lens fiber  (85) 
MMP1 Matrix metallopeptidase 1  (13) 
MMP3 Matrix metallopeptidase 3  (86) 
MMP7 Matrix metallopeptidase 7 (30) 
MMP8 Matrix metallopeptidase 8  (87) 
MMP9 Matrix metallopeptidase 9  (7) 
MMP10 Matrix metallopeptidase 10  (88) 
TIMP1 TIMP metallopeptidase inhibitor 1  (65) 
SFTPA1 Surfactant protein A1  (89) 
SFTPD Surfactant protein D  (89) 
S100A12 S100 calcium binding protein A12  (30) 
AGER Receptor for advanced glycation End products (16) 
LEP Leptin  (90) 
TGFB1 Transforming growth factor, beta 1. (91) 
SPP1 Secreted phosphoprotein 1 (92) 
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procedures, Samples collection, IRB, and statistical analysis have been described previously 
(84). The data is available at http://www.nhlbi.nih.gov/research/resources/ltrc. 
 Protein Isolation and Western Blot Analysis 
Lysates from control, IPF, or COPD lungs were harvested following the manufacturers’ protocol 
(Thermo Fisher Scientific™, Rockford, IL).  The concentrations of protein were measured 
(Bicinchoninic acid assay, Pierce, Rockford, IL).  For Western blot analysis, equal amounts of 
cellular extracts (10µg) were separated on 8% SDS-PAGE gels and transferred to PVDF-Plus 
membranes (GE Osmonics, Trevose, PA).  Western blots analysis were performed by using 
antibodies against MMP10 (1:1000; Novo biological Littleton, CO), GAPDH (1:500; Novo 
biological Littleton, CO).  After incubation with the respective secondary antibodies, specific 
bands were visualized by autoradiography using enhanced chemiluminescence according to the 
manufacturer’s instructions (PerkinElmer Life Sciences, Boston, MA).  Densitometry was 
performed using the shareware, ImageJ (http://rsbweb.nih.gov/ij/). 
 Immunohistochemistry 
Paraffin embedded IPF lungs, COPD lungs and control lungs were obtained from University of 
Pittsburgh Health Sciences Tissue Bank (Pittsburgh, PA).  Tissue slides were deparaffinized in 
serials ethanol and rehydrated in PBS.  Slides were blocked for one hour in 10% BSA and 
incubated with primary MMP10 antibody overnight.  A biotinylated donkey anti-rabbit 
secondary antibody was incubated for one hour after three times washes with PBS.  The 
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experimental details were previously described (93).  The images were visualized with 
Olympus™ microscope, PROVIS (Olympus America Inc., Melville, NY). 
 
 Statistical Analysis of Data 
Values were presented as mean or median ± SD.  Group comparisons were made using an 
unpaired, two-tailed Student’s t-test for normally distributed data.  A level of p < 0.05 was 
considered statistically significant.  Survival analysis of the cross sectional study was performed 
using Cox Time–independent model to examine covariates that change over time. Here baseline 
samples are used and the subjects were followed to event, or lost subjects follow up, or 
transplantation occurred. However, Cox Time dependent model examines covariates that change 
over time and it weighs more for samples collected before the events. Here serial samples are 
used and the subjects were followed to event, or lost subjects follow up, or transplantation 
occurred. In the biomarkers values were log transformed and dichotomized at the quartiles of the 
protein values. The p values were estimated by log rank test and the significance was established 
at 5%. Kaplan Meier curves plotted for each protein biomarker showing two lines: lower 3nd 
quartile and higher 3th quartile. Personal clinical and molecular mortality prediction index 
(PCMI) was created by using the following formula; PCMI = 114 *I(Male) + 2*(100%-FVC% 
predicted) + 3*(100% - DLco %predicted) + 111*I( Biomarker value ≥ median). Given male, I 
=1, female, I=0, Biomarker value ≥ median =1, and Biomarker value ≤ median =0 and Kaplan 
Meier survival curve was plotted using dichotomized PCMI level at median. The ROC of 
average PCMI of the individual significant biomarkers was estimated by using C statistic to 
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achieve optimal AUC.  We applied Cox Time-dependent model to examine covariates that 
change over time in the longitudinal cohort and plotted their Hazards ratios (95% CI) while 
adjusted or unadjusted for sex and age.  
3.3 RESULTS 
 Demographic and clinical information of subjects with IPF 
In this study, male consist of 73% of the cohort, former smokers were 72%, never smokers were 
24% and current smokers 4%.  Of this population 62% died or had lung transplant within 3 
years, among them 82 % were males.  To replicate the association of gender to IPF disease, we 
estimated the impact of gender in our cohort and found that male gender is 146 % associated 
with IPF disease (p= 0.02). Although it is well established that IPF disease is related to age, in 
this study the youngest IPF subject was 53 yr old and the oldest IPF subject was 79 yr. old. The 
overall average of age of the subjects in this cohort was 70 ± 6 yr. The pulmonary function test 
revealed that average of DLco = 46±17% years and FVC 64±15% predicted. The mean and 
median of the each protein measured and the PCMI are described in Table 3.2. 
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Table 3-2: The mean and median of candidate proteins for outcome in idiopathic pulmonary 
fibrosis  
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 Cross-sectional protein biomarkers and personal clinical and molecular mortality 
prediction index (PCMI) predict mortality in IPF subjects. 
 
Figure 3-1: Survival analysis of a cross sectional study for candidate biomarkers that predict IPF 
survival.  
Kaplan Meier survival for (A) ICAM1, (B) VCAM1, (C) S100A112, and (D) SFTPD. Blue line 
≤3rd quartile, Brown line ≥3rd quartile. In each case p< 0.05 
 
In this cross-sectional study, we replicated proteins reported as biomarkers for predicting IPF 
mortality (13, 30, 94).  We measured 250 samples from 61 IPF subjects to determine the level of 
24 plasma proteins.  Among these the univariate analysis classified 4 proteins, ICAM1 Hazard 
Ratio (HR) = 3.8 Confidence Interval (CI) (1.3, 11.3) p=0.02, VCAM1 HR=2.7 CI (1.1, 6.5) 
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p=0.02, S100A12 HR=1.6, CI (1.1, 2.3) p=0.01, and SFTPD HR=1.5, CI (1.1, 2.2), p=0.01) as 
predictors of IPF mortality after adjusting for age and gender (Figure 3.1). 
The personal clinical and molecular mortality prediction index (PCMI) of biomarkers 
predict the IPF mortality accumulatively and individually as presented in Figure 3.2 
 
 
Figure 3-2: Receiver operating characteristic curves for predicting IPF mortality by using 
personal clinical and molecular mortality Index (PCMI).   
 (A) PCMI was generated using this formula; PCMI = 114 *I(Male) + 2*(100%-FVC% 
predicted) + 3*(100% - DLco % predicted) + 111*I (Biomarker value ≥ median). Given male =1, 
female =0, Biomarker value ≥ median =1, and Biomarker value ≤ median =0.  Kaplan Meier plot 
for survival categorized at the median of PCMI: Blue line stands for PCMI ≤ median and brown 
line stands for PCMI = ≥ median. (B) ROC of combined individual significant biomarkers based 
on their PCMI with AUC = 80%, sensitivity 80and specificity 65%). 
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 Predictors for IPF mortality in longitudinal study 
To identify whether biomarkers in serial observation would better classify peripheral blood 
protein, we measured the concentrations of 24 proteins in IPF plasma by using multiplex ELISA 
(Aushon Biosystem, Billerica, MA). We hypothesize those changes in protein expressions could 
serve as novel predictors of mortality and disease monitoring. Using cox time dependent model, 
VCAM1, ICAM1, S100A12, MMP10, TIMP1, and IL-8 resulted as predictors of prognosis for 
IPF mortality while adjusted for gender and age as shown in Figure 3. 3.  
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Figure 3-3: Prediction of IPF mortality by using Cox Time dependent model in serial study.  
 Cox Time – dependent model was used to examine covariates that change over time. In the 
figures are Hazards ratios (95% CI) of adjusted (Black round plots) or unadjusted (Triangle 
black) for sex and age. The Hazards ratios were plotted: S100A12 (HR =1.59, P=0.012), 
VCAM1 (HR = 2.71, P= 0.024), ICAM1 (HR=3.83, P= 0.015), TIMP1 (HR=2.12, P = 0.013), 
MMP10 (HR=1.19, P = 0.035) and IL8 (HR= 1.25, P = 0.042). 
 MMP10 gene and protein expression were higher in IPF compared to COPD and 
control. 
We compared the transcripts expression level of MMP10 in control, IPF and COPD lungs and 
we found increased MMP10 in IPF lungs as shown in Figure 3.4A. To compare MMP10 protein 
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levels in IPF lungs to control lungs and COPD lungs, we performed western blot analysis and we 
found increased pro MMP10 and active MMP10 protein in IPF lungs (Figure 3.4B-D). To 
localize MMP10 in IPF lungs, we performed Immunohistochemistry (IHC) analysis. In normal 
histology lungs, MMP10 was located in the airway epithelialium region (Figure 3.5A). In IPF 
lungs MMP10 is in dense fibrotic region (Figure 3.5B). To Compare COPD as a disease control, 
we performed IHC in COPD lungs and found less MMP10 in COPD lungs compared to IPF 
lungs (Figure 5C).  
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Figure 3-4: MMP10 distinguishes IPF from control and COPD.   
(A) MMP10 mRNA level increased in IPF lung tissue (n= 83) compared to Control lung (n=63) 
and COPD lungs (n= 155) in microarrays data analysis, t-test p=<0.05 (B) MMP10 protein level 
in IPF, control and COPD. (C-D) demonstrates the densitometry of pro MMP10 and active 
MMP10. P<0.05 for t-test: control vs IPF (*) and IPF vs COPD (**), control vs COPD (***).  
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Figure 3-5 Localization of MMP10 in the control, IPF and COPD lungs.  
 MMP10 protein in the lung sections with brown color stained with DAB and counterstained by 
using Haematoxylin. (A)  Control lung, (B) MMP10 localized mostly in the IPF lungs in the 
fibroblastic foci, macrophages and lymphocytes. Less MMP10 was expressed in (C) COPD and 
(D) negative control.   
3.4 DISCUSSION 
In this study we demonstrated circulating protein biomarkers are predictors of IPF mortality in 
cross-sectional and longitudinal analysis.  These results confirmed previous reports (30) and 
added additional protein biomarkers with potential clinical and research implication.  In cross 
sectional study, we found ICAM1, VCAM1, S100A12, and SFTPD are predictors of IPF 
A B. 
D C 
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mortality.  Additionally, the personal clinical and molecular mortality prediction index (PCMI) 
of the biomarkers demonstrated predictive probability of IPF mortality.  In longitudinal study, 
the analyses revealed S100A12, VCAM1, ICAM1, TIMP1, MMP10, and IL-8 were predictors of 
IPF mortality.  Our data confirmed that in both cross-sectional and longitudinal studies VCAM1, 
ICAM1 IL-8 and S100A12 were consistent predictors of IPF mortality while MMP10 and 
TIMP1 were only novel predictors for IPF mortality in longitudinal study.  Therefore, 
stratification of IPF subjects using serial study maybe vital since the biomarkers status precedes 
the outcome events.  
In this study we found MMP10 and TIMP1 transcripts were associated with increased 
mortality in IPF. The finding MMP10 mRNA and protein are increased in IPF lungs as well as in 
peripheral blood maybe important to understand the mechanism of IPF pathology. MMP10 has a 
role in cancer metastasis (95) and is increased in human epithelial cancers (96). We and other 
investigators have reported that MMP10 predicts IPF mortality (74, 88) and is increased in lung 
and plasma of IPF (88).  Interestingly, we identified MMP10 immunostaining in epithelial cells, 
leukocytes and macrophages and fibrotic areas of the lung. This is consistent with the high rate 
of lung cancer in IPF subjects (97). 
 Tissue inhibitor metalloproteinase 1 (TIMP1) is a glycoprotein expressed in most human 
cells and tissues. As an inhibitor of MMP degradation, TIMP1  regulates extracellular matrix 
components (98, 99) and in tissues remodeling, repair, embryonal development and angiogenesis 
(98).  Although the role of TIMP1 in IPF diseases is unknown, it seems that both the MMPs 
inhibitory activities and and MMPs indepenent activity are involved in IPF disease.  
Among the other transcripts, we replicated ICAM1, VCAM1, S100A12, IL-8. In 
addition, SFTPD was also observed to be increased in IPF subject, which has been found to be 
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increased in acute lung injury patients when compared to control subjects.  SFTPD predicts 
mortality in IPF subjects (30).  Although the mechanism of SFTPD movement into blood is 
unclear, it is possible it occurs through the following mechanisms: (1) hypersecretion of SFTPD 
by diffuse hyperplasia of type II cells, (2) increased basolateral release and deposition into the 
extracellular matrix, or (3) increased lung epithelial and endothelial cell injury permitting 
leakage from pulmonary vasculature leading to increased serum/plasma level.  
ICAM1 is present in low concentrations on the surface of leukocytes and endothelial cells 
and ICAM1 facilitates leukocyte transmigration by binding to integrin subunit beta 2 (ITGB2 
aka leukocyte function associated Antigen-1), macrophage adhesion ligand-1 (MAC-1), and 
fibrinogen (100, 101).  In this regard, transforming growth factor beta 1, an integral mediator of 
pulmonary fibrosis, displays cross-talk with VCAM1 raising a potential signaling mechanism 
that may be relevant in human IPF (102). Indeed, our observation that elevated VCAM1 
concentrations in plasma of IPF subjects are linked with mortality offers support to premise that 
VCAM1 is involved in pathogenesis of IPF and may be considered as a biomarker.  More studies 
are needed to determine the biological role of VCAM1 in pulmonary endothelium to elucidate 
potential molecular mechanism(s) of VCAM1 up-regulation and implicate this adhesion 
molecule as causally related to the pathobiology.  
S100A12 is a protein localized to the cytoplasm and nucleus of cells and involved in the 
regulation of a number of cellular processes including cell cycle progression and differentiation. 
Serum S100A12 levels increase in patients that develop acute lung injury compared to those who 
do not develop ALI following postoperative sepsis (103). IL-8 is a chemoattractant and 
angiogenesis factor that signals inflammatory cells to site of inflammation (104) and we found 
the high level of IL-8 predict mortality.   
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Although we have very impressive results, the following limitations in studying 
peripheral blood proteins as biomarkers are evident: (1) many proteins interact and bind with 
each other leading to false positive results especially in long duration of storage, (2) processing 
samples right from blood draw, freezing or thawing cycles until to target proteins measurement 
are not globally standardized, and (3) multiplex ELISA prototypes may not be optimized for 
each protein in an assay of multiple proteins.  
In summary, we demonstrated that plasma protein expression levels of S100A12, 
VCAM1, ICAM1, TIMP1, MMP10, and IL-8 are predictors of IPF mortality over 3 years.  This 
is the first time group of IPF biomarkers have been studied in a longitudinal study. Our data 
demonstrates that peripheral blood biomarkers have capabilities to predict IPF mortality that 
could impact the treatment and clinical management of this incurable disease.
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 PAPER 3: E2F8 IS A CRUCIAL REPRESSOR OF COLLAGEN1 SYNTHESIS 
AND DEPLETED BY AN ORPHAN E3 LIGASE 
4.1 INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a lethal and refractory member of the idiopathic   
interstitial pneumonias, with a median survival time of ~3 years regardless of treatment (105). 
IPF is histologically characterized by patchy areas of active fibroblast proliferation (fibroblastic 
foci) that are associated with minimal inflammation and interspersed with areas of advanced 
fibrotic cystic changes (honeycombing) and normal appearing lung (11). Lung transplant, while 
definitive, is therapy for only a fraction of IPF patients, although newer therapeutics may limit 
loss of pulmonary function (106-108).  Studies using transcripts targeting in mice, transcriptomic 
studies, and better classification of interstitial lung diseases have led to a shift in the 
understanding of IPF(36).  IPF has shifted from “inflammation leading invariably to fibrosis” to 
a more complex model that includes repeated epithelial injury, and aberrant epithelial-
mesenchymal crosstalk leading to fibroblast activation, proliferation, and ultimately scarring 
(109).  Roles for new pathways within coagulation, apoptosis, angiogenesis, and development 
have been proposed(110).  Regardless of the proximate events, the final common pathway is the 
unremitting accumulation of fibroblasts and the deposition of extracellular matrix  (36). In IPF, 
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specifically, collagens 1A1 and 5A1 and elastin are excessively deposited in the interstitial 
compared to healthy subjects (31) (32).  
Extracellular matrix components cross-talk with fibroblasts affecting their behavior (111) 
and thus understanding how these components are produced is critical in IPF. The abundance of 
type 1 collagens (COL1A1 and COL1A2) regulated by mRNA synthesis and stability; for 
example, transforming growth factor beta 1 (TGFB1) and interleukin 4 (IL4) transcriptionally 
activate the COL1A1 and COL1A2 genes in human lung fibroblasts through combinatorial 
transactivation by SP1, NFКB, and STAT6 (112).  TGFB1 also increases COL1A1 mRNA 
stability (84).  Other transcriptional partners such as Yin Yang 1 (113), cis-acting promoter 
elements (CCAAT box) (114), and upstream signals (Rac1/MLK3/JNK/AP-1) activate COL1A1 
gene transcription (115).  Very few repressors of COL1A1, such as Fra-1 or FOXF1 have been 
identified although definitive regulation of the COL1A1 promoter by these proteins has not been 
assessed (116, 117).  
E2 transcriptional factor 8 (E2F8) is a member of E2F transcription factors that are 
divided into two groups, transcriptional activators (E2F1- E2F3) and transcriptional repressors 
(E2F4-E2F8).  E2F family of transcription factors is valuable in mammalian in regulating cell 
cycles.  E2F8 functions as repressor and has two DNA-binding domains (DBDs) that resemble 
the DBDs of typical E2F as well as their dimerization partner (DP) protein.  E2F8 binds a DNA 
sequences (15-base pair DNA fragment) similar to typical E2F proteins (118).  Interestingly, 
E2F8 was found to block fibroblast cells proliferation and silencing E2F8 induces cell 
proliferation (119, 120). E2Fs engage other factors such as Rb or DP proteins to control gene 
transcription (33). E2F1 deficient mice have more biliary fibrosis through Egr-1 (a zinc finger 
protein) (34), but overexpression of E2F1 inhibits type II collagen formation in cartilage (35).  
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E2F8 regulates embryonic development and the cell cycle by inhibiting E2F1, and controls 
angiogenesis and lymphoangiogenesis in zebrafish (121).  High-level expression of E2F8 
regulates cell proliferation and tumorigenesis in lung cancer and hepatocellular carcinoma (122-
124).   E2F8 facilitates hepatic fatty liver by regulating FABP3, that may ultimately be associated 
with hepatic fibrosis (125), suggesting that its function is highly cell- and context-specific.  
Ubiquitination tags proteins for degradation, either by the proteasome or lysosome, to 
regulate diverse processes (126),(127).  Ubiquitin linked to a target protein is orchestrated by a 
series of enzymatic reactions involving an E1 ubiquitin-activating enzyme, ubiquitin transfer from 
an E1-activating enzyme to an E2-conjugating enzyme, and last, generation of an isopeptide bond 
between the substrate’s ε-amino lysine and the C-terminus of ubiquitin catalyzed by an E3-
ubiquitin ligase (128).  Of the E3s, the SCF superfamily is the best studied (129).  The SCF 
complex has a multi-unit core consisting of Skp1, Cullin1, and Rbx1 (130).  This complex also 
contains a receptor subunit, termed F-box protein, which recruits substrates to the E3 catalytic 
core (131, 132).  Three families of F-box proteins exist: the L family contains a leucin-rich repeat 
(LRR) motif; the W family contains a WD repeat motif; and the O family F-box protein contains 
unknown motifs (133).  The protein level of E2F8 is decreased in IPF lungs, fibroblasts and 
bleomycin induced mice lung fibrosis.  It was targeted for ubiquitination and proteasomal 
degradation in hLF mediated by SCF F-box protein, FBX016 that leading to increased COL1A1 
synthesis. hLF transfected with Myc-tagged E2F8 plasmids encoding E2F8 suppressed 
fibroblasts proliferation or COL1A1 synthesis  and E2F8 shRNA constructs induced fibroblasts 
proliferation or COL1A1 synthesis. Interestingly, hLF co-transfected with a GLucCol1A1 
promoter-reporter construct with plasmids encoding E2F8 suppressed and induced by E2F8 
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shRNA.  Collectively, these studies offer a foundation for further research on the mechanistic 
roles of E2F8 and FBX016 in IPF pathogenesis. 
4.2 METHODS 
 Materials. 
Microarray reagents, arrays and scanner were purchased from Agilent Technologies 
(Wilmington, DE). The following antibodies were used: Collagen 1A1 (Rockland, Limerick, 
PA), β –actin (Sigma-Aldrich, St. Louis, MO), MMP10 (Novous Biological, Littleton, CO), 
E2F8 (Abcam, Cambridge, MA), FBX016 and Myc (Santa Cruz Biotechnology, Santa Cruz, 
CA). The following reagents used: cycloheximide (Inducer of protein degradation), MG132 
(Inhibitor of proteasomal protein degradation), Leupeptin (Inhibitor of lysosomal protein 
degradation), IgG, and ubiquitin (Santa Cruz Biotechnology, Santa Cruz, CA), bleomycin  and 
trichrome stain kit (Sigma-Aldrich, St. Louis, MO), the miRNA mini Kit and Effecten 
transfection reagent (Qiagen, Louisville, KY), the primers for collagen1A1 and qRT-PCR (ABI, 
Foster City, CA), E2F8 shRNA (Dharmacon, Lafayette, CO), the GLucCol1A promoter reporter 
construct (GeneCopoeia, Rockville, MD), the CytoSelect BrdU cell proliferation ELISA kit (Cell 
Biolabs, San Diego, CA) and Western Lightning Plus ECL (PerkinElmer, Boston, MA).  
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 Microarrays 
Lung Tissue Resource Consortium (LTRC) comprised of 4 clinical centers with core laboratories 
of tissues, radiology and clinical data that were coordinated in collecting data of COPD and IPF. 
For this study, we used 109 controls and 134 IPF samples. All samples were well phenotyped 
clinically, radiographically and physiologically and the diagnoses of IPF were established on the 
basis of American Thoracic Society (ATS) and European Respiratory Society (ERS) Criteria 
(11).  Total RNA were extracted, labeled and hybridized to Agilent 44k whole human genome 
microarrays (Agilent Technologies, Wilmington, DE).   
 Lung Protein isolation and western blot analysis 
Lysates from control and IPF lungs were collected (Thermo Fisher Scientific™, Rockford, IL), 
protein concentrations were measured (Pierce’s Bicinchoninic acid, Pierce, Rockford, IL). For 
Western blot analysis, equal amounts of cellular extracts (10µg) were separated on 8-10 % SDS-
PAGE gels and transferred to PVDF-Plus membranes (GE Osmonics, Trevose, PA). Western 
blots were performed with antibodies against E2F8, MMP10, FBX016, Anti-Collagen type 1 and 
Anti-Myc were diluted (1:1000) and β-actin (1:10000). After incubation with the respective 
secondary antibodies, specific bands were visualized by autoradiography using enhanced 
chemiluminescence according to the manufacturer’s instructions (PerkinElmer Life Sciences, 
Boston, MA). Densitometry was performed using the shareware, ImageJ 
(http://rsbweb.nih.gov/ij/). 
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 Cells culture, RNA extraction, and real-time PCR experiments. 
Early passages (1-3) of primary human lung fibroblasts (hLF) from the University of Pittsburgh 
Tissue Bank were cultured in F-12 medium supplemented with 10% fetal bovine serum (FBS) 
and antibiotic-antimycotic (Invitrogen, Carlsbad, CA). All experiments were performed on cells 
at 70-80% confluence. Treatment with E2F8 plasmid or a control empty vector and control 
shRNA or E2F8 shRNA were performed for 24 hrs. Immunoblots were performed as described 
above. The cellular total RNA were extracted from cultured cells on plates by QIAol lysis 
reagent and purified using the miRNeasy mini Kit from Qiagen (Louisville, KY). The RT-PCR 
was performed according to the manufacture’s protocol as described previously (134).  
The proliferation was detected using a CytoSelect BrdU cell proliferation ELISA. To 
determine BrdU incorporation into cellular DNA during cell proliferation, cells were grown on a 
96-well cell culture plate and transfected with E2F8 plasmid or a control empty vector and 
control shRNA or E2F8 shRNA using Effecten transfection reagent. After 12 hrs, medium was 
changed and cells were incubated for an additional 24 hrs. An aliquot of BrdU was then added to 
the medium and cells were incubated for an additional 3 hrs at 370C. After washing with PBS, 
cells were fixed for 30 min and BrdU incorporation into total cellular DNA was determined 
using anti-BrdU antibody.  
 Bleomycin murine model of lung fibrosis. 
All animals’ procedures were executed in accordance with approval of University of Pittsburgh 
Institutional Animal Care and Use Committee. Male and female C57BL/6 mice (6 to 8 weeks 
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old) were deeply anesthetized and bleomycin at 3 U/kg or saline control was administered 
intratracheally in a volume of 50 μL. After 16 days mice were sacrificed (CO2 inhalation and 
cervical dislocation) and the lungs were excised for determination of Collagen content using 
Masson trichrome staining. The images were visualized (PROVIS Olympus America Inc., 
Melville, NY). 
 Statistical Analysis  
The group comparisons between diseased and control subjects were performed using an unpaired 
two-tailed Student’s t-test for normally distributed data. A level of p<0.05 was considered 
statistically significant. The bands on immunoblots were quantified by using ImageJ, and then 
densitometric ratios were calculated.  The ratios data were statistically analyzed to discriminate 
their differences by using an unpaired student t-test.  Microarrays data were analyzed by cyclic-
LOESS normalization (135), Genomica (136), and SAM (136).  A 5% false discovery rate was 
used for significance and expressed as absolute fold change. 
4.3 RESULTS 
 E2F8 protein is a target for ubiquitin-mediated degradation in human lung 
fibroblasts (hLF). 
In mRNA screens of transcription factors in IPF lungs versus control human lungs, we assayed 
levels of various members of the E2F family and first observed a ~ 3-fold increase in steady-state 
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mRNA for E2F8 (Fig. 1A).  Interestingly, when assaying levels of E2F8 protein decreased in IPF 
(n=5) compared to controls (n=5) (Fig. 2 A-B).  Low levels of E2F8 were also seen in the 
fibroblasts isolated from IPF (n=4) lungs versus control (n=4) (Fig. 2C-D). To understand if 
E2f8 is rapidly degraded in IPF fibroblasts through proteasome, we exposed to hLF 
cycloheximide (CHX) to assess protein stability and observed that E2F8 has a short half-life (t ½ 
~1-2 h) (Fig. 3A) consistent with other transcription factors. E2F8 degradation was inhibited by a 
proteasome inhibitor (MG132) but not a lysosomal inhibitor (leupeptin). Transcription of a 
plasmid encoding Hemagglutinin tagged-ubiquitin (HA-Ub) in hLF increased E2F8 
polyubiquitination (Fig. 3B) and HA-Ub expression was sufficient to trigger E2F8 degradation 
(Fig. 3C).   
We next hypothesized that E2F8 itself must undergo proteolysis in IPF fibroblasts because 
it is depleted and yet its mRNA is increased 3-fold versus normal lung (Figure 1A). One 
possibility is that E2F8 is targeted by a ubiquitin E3 ligase for it elimination in IPF.  E2F8 is a 
phosphoprotein and because many E3 SCF-based proteins target phosphorylated substrates for 
ubiquitination (137), we performed an unbiased screen randomly examining ubiquitin E3 ligase 
receptor components, called F-box proteins, that might be expressed in IPF lung and trigger E2F8 
degradation. We found that FBX010, FB0X015, and FBX016 mRNA were increased IPF lungs 
compared to control lungs (Fig. 4A). Upon expression of one of these plasmids, FBX016, 
decreased levels of immunoreactive E2F8 compared to a control plasmid, FBX024 (Fig. 4B). In a 
bleomycin model of lung fibrosis, E2F8 protein levels were reduced and FBX016 levels modestly 
increased (Fig. 4C). To confirm specificity of FBX016 targeting E2F8, we performed Co-IP 
experiments where FBX016 was detected in the E2F8 immunoprecipitates (Fig.4D).  
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Figure 4-1 E2F8 mRNA in IPF lungs compared to control lungs in fold change. 
(A). Analysis of the micro mRNA levels of E2F transcription factor family members expressed 
in IPF lungs as fold change vs control lungs. The mRNAs were extracted from LGRC data by 
microarray profiling of lung tissues from control subjects (n=109) and subjects with IPF 
(n=134).  
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 Figure 4-2: E2F8 protein level is decreased IPF lungs and fibroblasts.   
 
E2F8 protein (94 kDa) in control (n=5) lungs and IPF (n=5) lungs. (B) Densitometry 
quantification of the immunoblot of E2F8 in lung tissues lysate (Image J). (C) Analysis of E2F8 
protein levels in fibroblasts isolated from control (n=4) and IPF (n=4) lungs. (D) Densitometry 
quantification of the immunoblot of E2F8 in fibroblasts (Image J). 
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Figure 4-3Ubiquitin-proteasome degradation of E2F8 in human lung fibroblasts.  
(A) Levels of E2F8 in hLF exposed to of cyclohexamide (CHX, 20 mg/ml) alone or in 
combinations with MG132 (20 mg/ml) or leupeptin (100mg/ml). (B) Ubiquitination of E2F8. 
Lysates from lung fibroblasts were subjected to immunoprecipitation with IgG or ubiquitin 
antibodies followed by immunoblotting for E2F8. (C) Expression of hemagglutinin-tagged 
ubiquitin (HA-Ub) in hLF induced degradation of E2F8 and increased total ubiquitination of 
proteins in cell lysates. Human lung fibroblasts transfected with various concentrations of 
plasmid encoding HA-Ub were analyzed by immunoblotting for E2F8 and β-actin.  
 
Figure 4.3 
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Figure 4-4: Fbxo16 triggers E2F8 degradation in human and mouse fibrotic lung.  
Expression of F-box proteins in IPF lungs versus control lungs. The mRNAs were extracted from 
LGRC data: Microarray profiling of lung tissues from control subjects (n=109) and subjects with 
IPF (n=134). (B) Histology of control lung and bleomycin induced mice lung fibrosis (C) 
FBXO16 targets E2F8 for degradation. The hLF were transfected with V5-tagged F-box proteins 
(0.4 mg) and a control FBX024 plasmid. Cells were than lysed for V5, E2F8, MMP10 and β-
actin levels by immunoblotting. MMP10 was used as a negative control. (C) Levels of 
expression of E2F8 and FBX016 proteins in lysates from a bleomycin- induced mouse model of 
lung fibrosis were analyzed by immunoblotting. (D). Ubiquitination reaction showing ability of 
FBX016 to directly polyubiquitinate (arrows) E2F8. 
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 E2F8 regulates collagen1A1 synthesis in lung fibroblasts. 
We examined if E2F8 transcriptionally suppresses collagen 1 levels in hLF because E2F1 
knockout mice are less prone to biliary fibrosis (34) and this protein may regulate type II 
collagen formation. We ectopically expressed a plasmid encoding Myc-tagged E2F8 in hLF and 
observed that levels of collagen 1A1 decreased with transfection of increasing amounts of E2F8 
plasmid (Fig. 5A). Conversely, depleting cells of E2F8 increased collagen 1A1 mRNA content in 
cells (Fig. 5B). Further, in these studies we also assayed steady-state collagen 1 (Col 1) mRNA 
in cells and observed that overexpression of E2F8 decreased Col 1 mRNA levels (Fig. 5D) 
whereas depletion of the transcription factor increases the transcript levels for this matrix-
associated protein (Fig. 5E). In a bleomycin fibrosis model, Col 1 levels increased (Fig. 5C). To 
confirm effects of E2F8 on inhibition of Col 1 gene transcription, we co-transfected human lung 
fibroblasts with a GLucCol1A1 promoter reporter construct together with a plasmid encoding 
E2F8 or an empty vector (Fig. 6A). Ectopic E2F8 expression in cells strongly repressed 
promoter-reporter activity over 50% versus control (Fig. 6B).  In reverse experiments, we 
knocked down E2F8 using shRNA in hLF which increased E2F8 silencing increased 
GLucCol1A1 promoter reporter activity almost 1.5 fold (Figure 4.6D).  
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Figure 4-5 E2F8 modulates collagen 1 levels.  
hLF were transfected with (A, D) various amounts of Myc-tagged E2F8 plasmids encoding E2F8 
or an empty vector, or (B, E) one of two E2F8 shRNA constructs or a control shRNA. (A, B) 
Cells were then lysed and levels of E2F8 and collagen 1 levels were determined by immunoblot 
analysis. (C) The levels of collagen 1 expression in lungs of mice treated with bleomycin. Upper: 
Normal lung structure of lung histology and below is damaged lung histology with blue color 
showing collagen 1 in a bleomycin- induced fibrosis. (D, E) Total cellular RNA was extracted 
from the lung fibroblasts using TRIzol reagent. Quantitative real-Time PCR was then performed 
using the Taqman Gold kit according to the manufacturer’s instructions. mRNA of collagen 1 
was measured.  *P<0.05  
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Figure 4-6: E2F8 represses collagen 1 gene transcription. 
Normal Lung fibroblasts were co-transfected with a GLucCol1A promoter-reporter construct and 
plasmids encoding E2F8 or an empty vector (A-B), or an E2F8 shRNA construct or a control 
shRNA (C-D). After 48 h cell culture, medium was collected for GLuc luminescent assays using 
a Secrete-PairTM Gaussia Luciferase Assay Kit which detects naturally secreted GLuc following 
the manufacturer’s instructions. Cell lysates were then analyzed by immunoblotting to determine 
transfection efficiencies (A, C). The data are from n=3 separate experiments. *P<0.05.   
 E2F8 plasmid inhibits and depletion of E2F8 induced lung fibroblast proliferation 
We hypothesized that E2F8 might play a role in IPF fibroblasts proliferation and the formation 
characteristic fibroblastic foci. Thus, we examined if E2F8 modulates fibroblast growth 
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behavior. We ectopically expressed Myc-tagged E2F8 in normal hLF (NHLF) or in hLF isolated 
from IPF lungs and assayed cell proliferation using BrdU labeling. We also depleted this 
transcription factor using shRNA as described above. As shown in figure 7, transfection of E2F8 
plasmid modestly reduced cell proliferation by ~25-35% in both NHLF and IPF fibroblasts (Fig. 
7A, C). In contrast, depleting cells of E2F8 increased cell growth despite low levels of E2F8 in 
IPF cells (Figure 4.7B, D).  
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Figure 4-7 E2F8 modulates fibroblast proliferation. 
The proliferation of hLF was detected using a CytoSelectTMBrdU cell proliferation ELISA kit. 
To determine BrdU incorporation into cellular DNA during cell proliferation, normal hLF (NHF) 
(A, B) or IPF fibroblasts (C, D) on a 96-well cell culture plate were transfected with: (A, C) 
plasmids encoding E2F8 or an empty vector, or (B, D) E2F8 shRNA or a control shRNA using 
Effecten transfection reagent. The BrdU incorporated into cellular DNA during cell proliferation 
was detected using an anti-BrdU antibody. The data from each panel represents n=4 separate 
experiments. *P<0.05.  
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4.4 DISCUSSION 
 
In this study, we investigated the role of E2F8 in the pathogenesis of IPF disease and the results 
suggest that: (A) E2F8 mRNA is increased in IPF lung, (B) E2F8 is a crucial transcriptional 
repressor of collagen 1A1 levels in human lung fibroblasts, (C) E2F8 protein levels are depleted 
in IPF lung and IPF lung fibroblasts because of SCF-FBX016-mediated ubiquitin-proteasomal 
degradation, (D) loss of E2F8 appears to contribute at least in part to the pathobiology of 
fibroblastic growth and fibrotic response observed in humans with IPF disease. This data offers a 
biologic foundation for future investigations of the molecular regulation of this transcriptional 
repressor (E2F8) and collagen1A1 synthesis in IPF.             
Previous studies have found that E2F8 levels increase in lung cancer (122), 
hepatocellular carcinoma (138) (123) and melanoma (139).  However the biological functions 
appears to cell type and context specific.  In cancer cells, silencing E2F8 inhibited lung cancer 
cell proliferation, and tumor growth.  Increased E2F8 predicted mortality of adenocarcinoma 
subjects (122).  Taken together E2F8 has opposite functions in cancer cells compared to the 
reports in normal mouse embryonic fibroblasts.  E2F8 inhibits cells proliferation and silencing 
E2F8 induces cell proliferation (119, 120).  Since in this study we examined E2F8 in normal 
human lung fibroblasts and IPF lung fibroblasts, our data replicated that suppression of 
fibroblasts proliferation by overexpression of E2F8 and knocking down E2F8 in lung fibroblasts 
yielded to induction of fibroblasts proliferation.  Although transcript expression of E2F8 is 
increased in IPF as in cancers, we found that E2F8 protein is decreased in IPF lung fibroblasts.  
To understand these phenomena, we investigated whether a FBX016 could limit E2F8, by 
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ubiquitination and proteasomal degradation in the fibroblasts of IPF subjects.  FBX016 might 
serve as a unique molecular target for therapeutic intervention in fibrotic illness using F-box 
pharmaceutical inhibitors. 
Because the histology of usual interstitial pneumonia exhibits active fibroblasts 
proliferation (fibroblastic foci), honeycombing and accumulation of extracellular matrix such as 
COL1A1, fibronectin and elastin (31, 32, 36), we co-transfected E2F8 plasmid in hLF with a 
GLucCol1A promoter reporter construct and noted that ectopic E2F8 expression in cells 
repressed COL1A1 promoter-reporter activity. Complementary knock down of E2F8 in hLF 
increased GLucCol1A promoter reporter activity.  This data suggest that E2F8 is a key inhibitor 
of COL1A1 synthesis in human lung fibroblasts. 
TGFB1 is a key mediator of fibrotic lung remodeling and it is conceivable that decreased 
expression of E2F8 protein or increased E2F8 mRNA concentrations in IPF lungs or fibroblasts 
may function as a sign of active fibrotic lung transformation because low level of E2F8 in mouse 
lungs was observed in a murine model of bleomycin-induced pulmonary fibrosis. As such the 
possibility that bleomycin is involved in regulation of E2F8 is relevant for physiological process 
of lung fibrosis. We hypothesized that E2F8 could play a role in IPF fibroblasts proliferation and 
forming characteristic foci in IPF lung. Thus, we examined if E2F8 modulates fibroblast growth 
behavior. We ectopically expressed Myc-tagged E2F8 plasmid in normal hLF or in hLF isolated 
from IPF lungs and assayed cell proliferation using BrdU labeling. We also depleted this 
transcription factor using shRNA. Transfection of E2F8 plasmid modestly reduced cell 
proliferation by ~25-35% in both NHLF and IPF fibroblasts. Similarly, depleting cells of E2F8 
increased cell growth despite low levels of E2F8 in IPF cells. Our studies also raise additional 
questions as to the role of transcriptionally activated E2F8 on modulating fibroblast phenotypic 
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behavior because E2F8 has been reported to be involved in modulating growth activity in mouse 
and human uterine decidualization (140), and placental development (141). 
Although we offer interesting results, we are aware of limitation that we did not 
performed in vivo mouse model of E2F8 gene loss or gain experiment.  However, our findings in 
vitro experiments on human lung fibroblasts are relevant mechanistic information and should 
encourage future IPF studies.  
Our data suggest that E2F8 transcript is increased and E2F8 protein is decreased by 
proteasomally degradation in IPF lung and this was confirmed by treating fibroblasts from IPF 
subjects with the proteasome inhibitor, MG132 and that these E2F8 protein levels can be restored 
by interrupting the mechanisms that mediate protein degradation. These results are novel and 
important because they demonstrate that E2F8 may act to repress COL1A1 gene transcription 
and this could lead to a better understanding of IPF pathobiology and potential therapeutic 
targets.
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 CONCLUSION 
In this project we investigated the complex problems of IPF disease: (1) lack straight forward 
method of diagnosis, (2) IPF is a chronic, unpredictable, and incurable lung disease, (3) IPF is 
still named “Idiopathic” that means the etiology of this particular usual interstitial pneumonia is 
unknown.  Therefore, to address these 3 fundamental issues, we applied the following 
experimental methodologies: transcriptomic analysis, plasma protein biomarkers discovery, 
molecular mechanistic evaluations. 
We demonstrated that advance bioinformatics modeling and computation, we could 
distinguish IPF or COPD from control through their specific transcript expressions. We were 
able to reduce 29232 transcripts to 44 transcripts.  The ROC of IPF vs control was significant 
with an AUC = 0.85 (95% CI), sensitivity 85% and specificity 91%.  The ROC of IPF vs COPD 
was significant with an AUC= 0.87 (95% CI), sensitivity 86% and specificity 90%.  Although 
this is very interesting results, we are aware that utilitizing lungs transcripts has major limitations 
in clinical practice because biopsy is invasive procedure and microarrays is an expensive and 
labor intensive method.  The next step that could bring this bioinformatics finding to clinical 
settings is to measure the corresponding proteins of the transcripts in the blood samples. 
Following that experiment, a diagnostic protein biomarkers panel could be created after a 
validation study is being performed using independent cohort. Therefore, future studies that 
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would like to explore these methods to distinguished stages of disease or group of disease should 
be encouraged. 
In the prognostic biomarker study, we replicated previously described predictors of IPF 
mortality in cross-sectional study. In longitudinal study, our data confirmed that in both cross-
sectional and longitudinal studies S100A12, VCAM1, ICAM1, and IL-8 were consistent 
predictors of IPF mortality and added MMP10 and TIMP1 as novel predictors for IPF mortality 
in longitudinal study. Therefore, stratification of IPF subjects using serial studies biomarkers will 
be vital since the concentration of biomarkers status precedes the outcome events weighted more 
in the analysis.  This is the first time group of IPF biomarkers have been studied in a longitudinal 
study.  As IPF is clinically variable disease, stratifying IPF subjects based on risk of mortality 
could assist in selecting IPF subject for lung transplant and clinical trial studies.  Our data 
demonstrates that peripheral blood biomarkers have capabilities to predict IPF mortality.  
Clearly, these prognostic biomarkers, along with other reported IPF biomarkers, will require 
further validation. Nonetheless, this approach appears to be worthy of additional investigation 
and could impact the treatment and clinical management of this incurable disease     
E2F8 is a crucial transcriptional repressor of COL1A1 levels in human lung fibroblasts. 
Loss of E2F8 appears to contribute, at least in part to the pathobiology of fibroblastic growth and 
fibrotic response observed in humans with IPF disease. These new biochemical and molecular 
observations offers a biologic foundation for future projects aiming to investigate the molecular 
regulation of E2F8, COL1A1 synthesis, and lung fibroblast proliferation in IPF.  In addition, 
these observations support restoration of E2F8 function, possibly by small molecule compounds, 
as a valid target for IPF therapy. 
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In summary, our transcriptomic and plasma proteins analyses revealed the utility of 
biomarker discovery in advancing precision medicine in IPF.  Together these finding provide 
novel insights that may improve IPF diagnosis, prognostic and potential drug discovery.    
 
 
61 
 
APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1: ICAM1.  
Receiver operating characteristic curves for predicting IPF mortality by using personal clinical 
and molecular mortality Index (PCMI).  (Left panel)  PCMI was generated using this formula; 
PCMI = 114 *I(Male) + 2*(100%-FVC% predicted) + 3*(100% - DLco %predicted) + 111*I ( 
Biomarker value ≥ median). Given male =1, female =0, Biomarker value ≥ median =1, and 
Biomarker value ≤ median =0.  Kaplan Meier plot for survival categorized at the Median of 
PCMI: Blue line stands for PCMI ≤ Median and brown line stands for PCMI ≥ Median.  (Right 
62 
 
Panel) ROC of combined individual significant biomarkers based on their PCMI with AUC = 
80% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2: VCAM1. 
Receiver operating characteristic curves for predicting IPF mortality by using personal clinical 
and molecular mortality Index (PCMI).  (Left Panel)  PCMI was generated using this formula; 
PCMI = 114 *I(Male) + 2*(100%-FVC% predicted) + 3*(100% - DLco %predicted) + 111*I( 
Biomarker value ≥ median). Given male =1, female =0, Biomarker value ≥ median =1, and 
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Biomarker value ≤ median =0.  Kaplan Meier plot for survival categorized at the Median of 
PCMI: Blue line stands for PCMI ≤ Median and brown line stands for PCMI ≥ Median. (Right 
Panel) ROC of combined individual significant biomarkers based on their PCMI with AUC = 
73% 
 
 
 
 
Supplemental Figure 3: S100A12.   
Receiver operating characteristic curves for predicting IPF mortality by using personal clinical 
and molecular mortality Index (PCMI).  (Left Panel)   PCMI was generated using this formula; 
PCMI = 114 *I(Male) + 2*(100%-FVC% predicted) + 3*(100% - DLco %predicted) + 111*I( 
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Biomarker value ≥ median). Given male =1, female =0, Biomarker value ≥ median =1, and 
Biomarker value ≤ median =0.  Kaplan Meier plot for survival categorized at the Median of 
PCMI: Blue line stands for PCMI ≤ Median and brown line stands for PCMI ≥ Median. (Right 
Panel)  ROC of combined individual significant biomarkers based on their PCMI with AUC = 
80% 
 
 
Supplemental Figure 4: SFPD.   
Receiver operating characteristic curves for predicting IPF mortality by using personal clinical 
and molecular mortality Index (PCMI).  (Left Panel)  PCMI was generated using this formula; 
PCMI = 114 *I(Male) + 2*(100%-FVC% predicted) + 3*(100% - DLco %predicted) + 111*I( 
Biomarker value ≥ median). Given male =1, female =0, Biomarker value ≥ median =1, and 
Biomarker value ≤ median =0.  Kaplan Meier plot for survival categorized at the Median of 
PCMI: Blue line stands for PCMI ≤ Median and brown line stands for PCMI ≥ Median.  (Right 
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Panel) ROC of combined individual significant biomarkers based on their PCMI with AUC = 
78% 
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